IMbrave050 Update Questions Adjuvant Atezo-Bev in HCC : J Hepatol | May 2026

Introduction

Recurrence after curative-intent resection or ablation remains one of the greatest challenges in Hepatocellular Carcinoma management, with early relapse rates remaining high even after apparently successful treatment. Following the landmark IMbrave150 study, the combination of Atezolizumab plus Bevacizumab became standard first-line therapy for unresectable HCC, generating major interest in extending this strategy into the adjuvant setting for high-risk disease.

Problem Statement

The initial interim analysis of the IMbrave050 trial demonstrated a significant recurrence-free survival benefit with adjuvant atezolizumab plus bevacizumab after curative-intent therapy for high-risk HCC. However, whether this early benefit would remain durable with longer follow-up and ultimately translate into overall survival improvement remained uncertain.

Summary

IMbrave050 randomized patients with high-risk HCC following curative-intent resection or ablation to receive one year of adjuvant atezolizumab plus bevacizumab or active surveillance. The original interim analysis generated considerable enthusiasm after demonstrating improved recurrence-free survival with combination immunotherapy and antiangiogenic therapy.

However, this updated analysis substantially alters interpretation of the study. With longer follow-up, the initially observed recurrence-free survival advantage was no longer sustained. The updated recurrence-free survival hazard ratio moved from the previously significant 0.72 to 0.90, indicating loss of the earlier statistical and clinical benefit signal.

Overall survival data also remained immature at the second interim analysis, with no evidence of survival advantage emerging thus far. Importantly, the overall survival hazard ratio numerically favored the surveillance arm, although confidence intervals remained wide and definitive conclusions cannot yet be drawn because of limited event maturity.

Despite the disappointing efficacy update, the long-term safety profile remained manageable and consistent with known toxicities of both agents. No unexpected safety concerns emerged with prolonged follow-up, reinforcing the relative tolerability of the regimen in appropriately selected patients with preserved liver function.

These findings are highly important because IMbrave050 represented the first positive immunotherapy-based adjuvant trial in HCC at initial reporting and had raised hopes for a paradigm shift in postoperative management. The updated results now emphasize the complexity of interpreting early recurrence-free survival signals in immunotherapy studies and highlight the necessity of mature longitudinal follow-up before widespread adoption of perioperative strategies.

Biologically, the findings suggest that residual micrometastatic disease after curative-intent HCC therapy may possess heterogeneous immune sensitivity. It is also possible that recurrence dynamics in HCC are influenced not only by metastatic relapse but also by de novo carcinogenesis within chronically diseased cirrhotic liver tissue, potentially limiting the durability of adjuvant immune-based approaches.

Importantly, exploratory subgroup analyses suggested that certain patient subsets may still derive benefit, indicating that biomarker-guided perioperative immunotherapy strategies remain an important future research direction. Effective perioperative therapy continues to represent a major unmet need in HCC given persistently high recurrence rates after surgery or ablation.

Overall, the updated IMbrave050 analysis does not support routine use of adjuvant atezolizumab plus bevacizumab for all patients with high-risk HCC following curative-intent treatment. The study nevertheless provides critical lessons for future perioperative immunotherapy trial design and reinforces the importance of refined patient selection strategies in early-stage hepatocellular carcinoma.